HC Wainwright Trims Actinium Pharmaceuticals (NYSE:ATNM) Target Price to $4.00

Actinium Pharmaceuticals (NYSE:ATNM) had its price target reduced by HC Wainwright from $50.00 to $4.00 in a report issued on Tuesday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q3 2024 earnings at ($0.36) EPS, Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($1.36) EPS, FY2025 earnings at ($0.94) EPS, FY2026 earnings at ($0.92) EPS, FY2027 earnings at ($1.03) EPS and FY2028 earnings at ($1.12) EPS.

Other equities research analysts also recently issued research reports about the company. Stephens assumed coverage on Actinium Pharmaceuticals in a research report on Tuesday, May 14th. They set an overweight rating and a $25.00 target price on the stock. StockNews.com lowered shares of Actinium Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, August 5th. Maxim Group reduced their target price on Actinium Pharmaceuticals from $30.00 to $5.00 and set a buy rating on the stock in a research note on Tuesday. Finally, Cantor Fitzgerald restated an overweight rating and set a $21.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 30th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Actinium Pharmaceuticals has a consensus rating of Moderate Buy and an average price target of $11.43.

Actinium Pharmaceuticals Price Performance

NYSE:ATNM traded down $0.36 during trading hours on Tuesday, reaching $2.05. The stock had a trading volume of 890,374 shares, compared to its average volume of 484,717. The company has a market capitalization of $61.06 million, a P/E ratio of -1.19 and a beta of 0.20. Actinium Pharmaceuticals has a 12-month low of $1.33 and a 12-month high of $10.24.

Actinium Pharmaceuticals (NYSE:ATNM) last announced its quarterly earnings data on Monday, August 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02. As a group, analysts anticipate that Actinium Pharmaceuticals will post -1.57 earnings per share for the current year.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Sanders Morris Harris LLC bought a new stake in Actinium Pharmaceuticals in the 1st quarter worth $78,000. Renaissance Technologies LLC purchased a new stake in shares of Actinium Pharmaceuticals during the second quarter worth about $142,000. Rhumbline Advisers grew its stake in shares of Actinium Pharmaceuticals by 23.4% in the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after purchasing an additional 7,525 shares during the last quarter. Virtu Financial LLC increased its holdings in Actinium Pharmaceuticals by 319.2% during the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock valued at $642,000 after purchasing an additional 62,459 shares during the period. Finally, Bank of New York Mellon Corp raised its position in Actinium Pharmaceuticals by 28.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after purchasing an additional 19,035 shares during the last quarter. 27.50% of the stock is currently owned by institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.